South San Francisco, California, USA, November 15, 2026
IDEAYA Biosciences, Inc. has announced the nomination of IDE101 as a new development candidate, marking an important milestone in the company’s precision oncology research programme. IDE101 is a potential first-in-class, dual cyclin-dependent kinase (CDK) inhibitor being developed to target cancers associated with CDKN2A deficiency, a genetic alteration frequently observed across several types of solid tumours. The investigational small molecule is designed to address the loss of CDKN2A-mediated tumour suppressor function, which plays an important role in controlling cell growth and preventing uncontrolled cancer development. According to IDEAYA, CDKN2A deficiency occurs in approximately 10–15% of all solid tumours, including around 70% of pancreatic ductal adenocarcinoma (PDAC) cases. The company plans to investigate IDE101 both as a standalone treatment and in combination with other targeted therapies, including RAS inhibitors and its proprietary PRMT5 inhibitor IDE892. The development candidate nomination represents a significant step towards advancing a new therapeutic strategy for molecularly defined cancer populations with substantial unmet medical needs.
IDE101 Targets CDKN2A Deficiency in Solid Tumors
CDKN2A is an important tumour suppressor gene involved in regulating the cell cycle and preventing uncontrolled cellular proliferation. When this gene is lost or inactivated, cancer cells can develop mechanisms that allow them to grow and divide without normal biological regulation. IDE101 is designed as a highly potent and selective dual CDK inhibitor that targets key drivers of tumour development associated with CDKN2A deficiency. By addressing vulnerabilities created by the loss of tumour suppressor activity, the investigational molecule aims to interfere with cancer cell growth and survival. IDEAYA identified IDE101 through its iterative, physics-based ligand design and optimisation platform, which combines computational approaches with medicinal chemistry to discover and improve targeted drug candidates. The company reported that IDE101 has demonstrated encouraging preclinical activity in CDKN2A-deficient tumour models, both as a monotherapy and in combination with other targeted inhibitors. These findings provide an initial scientific foundation for further investigation. However, the reported activity is based on preclinical research, and the compound has not yet been evaluated for clinical efficacy or safety in human participants. Its potential therapeutic benefits will need to be established through subsequent clinical development.
Combination Strategy Could Expand Cancer Treatment Potential
IDEAYA plans to explore IDE101 through rational combination strategies designed to target multiple molecular vulnerabilities within cancer cells. One major development opportunity involves combining IDE101 with RAS inhibitors for pancreatic cancer, particularly because pancreatic ductal adenocarcinoma frequently contains alterations affecting the CDKN2A pathway and oncogenic RAS signalling. Targeting both tumour suppressor loss and oncogenic dependencies could potentially provide a more comprehensive approach to disrupting cancer growth. Another planned strategy involves combining IDE101 with IDE892, IDEAYA’s proprietary investigational PRMT5 inhibitor, in MTAP-deleted solid tumours. CDKN2A and MTAP genes are located close to each other on chromosome 9p21, meaning they are frequently co-deleted in certain cancers. This genetic relationship creates opportunities for developing combination therapies that exploit multiple weaknesses in tumour cells. IDEAYA has reported encouraging preclinical combination findings involving PRMT5 and pan-RAS inhibitors. The company intends to present additional information about IDE101’s preclinical profile and combination research at its London Research and Development Day. These planned investigations could help guide future development priorities and identify patient populations most likely to benefit from the treatment approach.
IND-Enabling Studies Target 2027 Regulatory Milestone
Following the development candidate nomination, IDEAYA has initiated IND-enabling studies to support the next stage of IDE101’s development. These studies are intended to generate the necessary nonclinical safety, pharmacological and supporting data required before submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). The company is targeting an IND submission during the first half of 2027, subject to satisfactory completion of the ongoing preclinical and IND-enabling programme. An IND application would allow IDEAYA to seek regulatory authorisation to begin clinical testing in humans, provided the FDA’s requirements are met. The planned regulatory milestone represents an important transition from early drug discovery towards potential clinical development. IDEAYA is a precision medicine oncology company focused on developing targeted therapeutics for genetically defined cancer populations through small-molecule drug discovery, structural biology, bioinformatics and molecular diagnostics. The nomination of IDE101 further expands its oncology pipeline and reinforces its strategy of targeting specific biological vulnerabilities in cancer. If supported by future clinical studies, IDE101 could offer a new targeted treatment approach for patients with CDKN2A-deficient solid tumours, including difficult-to-treat pancreatic cancers. The upcoming development programme will determine whether its promising preclinical findings can translate into meaningful clinical benefits.
Source: IDEAYA Biosciences press release



